News
Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...
In a report released today, Sven Merkt from Barclays maintained a Sell rating on Sage Group plc (SGE – Research Report). The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback